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Abstract 
Background: Disparities between U.S. population groups in cancer incidence, treatment and 
outcome have been well documented. Literature evidence is scarce regarding the impact of 
patient navigator programs on elimination of these differences. 
Methods: This is a retrospective case series analysis .The pre -navigation group included 
patients diagnosed between January 1, 1997 and December 31, 1999. The post -navigation 
group included patients diagnosed between January 1, 2000 and December 31, 2003. Cancer 
stage, time from presentation to treatment and treatment outcome were compared by re-
view of medical records.  
Results: Three hundred and thirty five women were diagnosed between January 1, 1997 and 
December 31, 2003. Thirteen patients were ineligible, 103 women in the pre- navigation 
group, and 219 women in the post-navigation group. 157 (72%) received navigation services. 
The median time to first treatment was decreased by 9 days (42 days in pre -navigation group 
compared to 33 days in post -navigator group). Race, insurance and clinical presentation did 
not influence the time to treatment.  
Conclusions: Navigation program did not influence the stage of presentation or the overall 
survival of women. There was a modest decrease in the time between initial presentation and 
definitive therapy. The utility of navigator programs is likely to vary with each institution. 
Key words: Patient Navigation, breast cancer, survival, underserved population 
Introduction 
Disparities  between  U.S.  population  groups  in 
cancer incidence, treatment and outcome have been 
well  documented.  [1-4]  Most  commonly,  racial  and 
socioeconomic  variations  in  cancer  outcomes  have 
been  investigated.  African-Americans,  in  particular, 
are disproportionately affected by the morbidity and 
mortality  of  neoplastic  diseases,  with  higher  cancer 
incidence rates among men and higher cancer mor-
tality  rates  among  both  men  and  women  than  that 
observed  in  other  population  groups.  [2,5]  In  addi-
tion,  population  measures  of  socioeconomic  status 
have also been associated with cancer outcomes. Peo-
ple living in economically disadvantaged areas of the 
country  have  been  consistently  shown  to  have  a 
higher cancer-associated mortality. [6-8] 
Socioeconomic and racial or ethnic disparities in 
cancer  outcomes  can  be  partially  explained  by  a 
number of factors including health care access, quality 
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of  care,  the  presence  of  co-morbid  conditions,  and 
tumor or host biology. While we are acquiring a better 
understanding of why disparities in cancer outcomes 
exist, there is very little information about effective 
means of eliminating those differences.  
An increasingly popular approach to improving 
cancer care outcomes has been navigator programs. 
The first patient navigator program was introduced 
by Dr Harold Freeman, a breast surgeon at the Har-
lem Hospital in New York City. He observed a pattern 
of  late  stage  presentation  in  breast  cancer  patients 
where the primary barrier to early, effective treatment 
was the inability to access medical care in a timely 
manner. The Patient Navigation program at Harlem 
Hospital was designed to overcome this barrier and 
the success of his efforts resulted in the establishment 
of patient navigation programs throughout the coun-
try. [9-11] 
 Patient navigators are members of the commu-
nity who have a clear understanding of the local social 
and cultural issues and are simultaneously aware of 
the functioning of the health care system. They have 
established contacts with the medical providers, par-
ticularly  specialists  in  surgery,  radiation  oncology, 
medical oncology and radiology, as well as with the 
hospital support services such as social work and fi-
nancial counseling. The most important role of patient 
navigation is to assist an individual with a suspicious 
cancer-related  finding  to  receive  a  timely  diagnosis 
and treatment. The navigator accomplishes this most 
effectively  through  one-on-one  contact  with  the  pa-
tient from the time of initial suspicion of cancer di-
agnosis. This process is intended to eliminate barriers 
to  diagnosis  and  treatment. [9]  While  this  was  the 
primary focus of our Patient Navigators, many dif-
ferent  models  of  patient  navigation  are  being  em-
ployed  across  the  country,  having  very  different 
goals. Many are hospital based programs focused on 
improving clinical care and patient satisfaction in the 
hospital setting. They might not necessarily focus to-
wards improving health disparities. [11] 
While patient navigation programs have spread 
throughout  the  country,  their  impact  upon  cancer 
outcomes is understudied. [11,12] Through the eval-
uation of the processes and outcomes of breast cancer 
care at a safety net hospital over the time that a navi-
gator program  was adopted, this  study attempts to 
better define the impact of such programs. 
Materials and Methods 
Patient Population. All women with adenocarci-
noma  of  the  breast  diagnosed  at  Truman  Medical 
Center in Kansas City, Missouri between January 1, 
1997 and December 31, 2003 were eligible for inclu-
sion  in  this  study.  The  only  women  excluded  from 
analysis  were  those  who  received  their  primary 
therapy elsewhere (n = 7). 
Study Design. This was a retrospective case series 
analysis.  Truman  Medical  Center  is  the  safety  net 
hospital for Kansas City. With the generous assistance 
of the American Cancer Society, a Navigator program 
began  serving  patients  in  January  2000.  Eligible 
women with a breast cancer diagnosed between Jan-
uary 1, 1997 and December 31, 1999 were considered 
the standard management group. Women with breast 
cancer  diagnosed  between  January  1,  2000  and  De-
cember 31, 2003 were considered the Patient Naviga-
tor group. 
Intervention. The Patient Navigator program in-
cluded  three  health  care  facilitators.  Women  were 
identified by their treating providers and offered en-
rollment in the program at or around the time of their 
breast cancer diagnosis. This  was most often at the 
time of presentation to the Breast Clinic for evaluation 
of an abnormal mammogram or palpable breast mass. 
Participation was entirely voluntary. 
Women who chose to participate in the Naviga-
tor program were provided with added assistance in 
scheduling  appropriate  diagnostic  and  consultative 
services, arranging transportation and child care for 
scheduled appointments, access to a large collection 
of  educational  materials,  and  one-on-one  emotional 
support through the initial diagnosis and treatment 
process.  Subjects  who  chose  to  be  navigated  were 
provided with cell phones for appointment remind-
ers, when needed. The navigators followed them on 
their  subsequent  clinic  visits  to  promote  adherence 
with treatment recommendations and help with daily 
interferences with treatment including providing cab 
passes for transportation and child care services. They 
acted as advocates through the process necessary to 
obtain financial assistance with health care expenses 
(Medicaid and hospital/clinic discount applications). 
Finally, they often served as an informal contact be-
tween patients and other health care providers, asking 
for  more  information,  reporting  changes  in  clinical 
status and treatment toxicities. 
Data Collection and Analysis. Information on each 
patient was obtained by review of their medical rec-
ord  and  Tumor  Registry  entry.  Demographic  data, 
tumor histology and staging, cancer treatment infor-
mation and patient outcome data were obtained. In 
addition, a detailed timeline of cancer care was con-
structed. The date of first evaluation was defined as: 
1) the date that the patient first contacted the health 
care system with a concern that led to the diagnosis of 
breast cancer (this was most commonly a visit to a 
primary care provider with a palpable breast abnor- Journal of Cancer 2011, 2 
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mality), or 2) the date of an abnormal screening exam 
(most often mammogram) for clinically asymptomatic 
tumors. The date of first treatment was defined as the 
date that the patient began definitive therapy for the 
cancer,  typically  the  date  of  a  therapeutic  surgical 
procedure or, if surgery was not the initial therapy, 
the date that chemotherapy or hormonal therapy was 
begun. 
The  primary  outcome  evaluated  in  this  study 
was mean time to definitive therapy, defined as the 
difference between the date of first evaluation and the 
date of definitive therapy. Secondary outcomes were 
the proportion of women receiving definitive therapy 
within 60 days of clinical presentation and the time 
from surgery to beginning adjuvant therapy. All sta-
tistical analyses were performed with SPSS for Win-
dows  software  (SPSS  16.0,  SPSS,  Chicago,  IL).  De-
scriptive  data  were  compared  using  χ2  test.  A  two 
tailed p value of < 0.05 was considered significant for 
all tests. Time to event analysis was performed using 
the  Kaplan-Meier  method  and  compared  with  the 
log-rank test. The impact of potentially confounding 
variables was considered using Cox regression analy-
sis. 
With  a  two  sided  α  of  0.05  and  an  expected 
sample size of 300 patients, the study had a power of 
0.85  to  detect  a  five  day  difference  in  the  primary 
outcome. The power was 0.80 to detect a 15% differ-
ence in the proportion of women receiving definitive 
therapy in 60 days. 
Results 
Three hundred thirty five women with adeno-
carcinoma  of  the  breast  were  diagnosed  between 
January  1,  1997  and  December  31,  2003.  
 Seven patients received their cancer treatment else-
where and the first date of clinical contact for a breast 
cancer related sign or symptom could not be clearly 
determined in an additional six patients. These thir-
teen  patients  were  excluded  from  further  analysis, 
leaving a final study population of 322 women; 103 
women in the pre navigator group, and 219 women in 
the post navigator group. Of the 219 women in the 
patient  navigation  group,  157  (72%)  accepted  and 
received navigation services. 
Table  1  outlines  the  demographic  and  tumor 
characteristics of the women studied. 
The women  in this  study  had a slightly lower 
median age, 55 years, than observed nationally and 
were evenly divided between Caucasian and African 
American  race.  One  remarkable  difference  between 
the  two  study  groups  was  the  proportion  of  unin-
sured women, which was much lower during the pe-
riod of time when patient navigation was available. 
This decrease in the number of uninsured women was 
accounted for by a similar increase in the number of 
women  with  Medicaid  insurance  in  the  navigated 
group.  Insurance  status  was  measured  six  months 
after diagnosis (at the time of case accession in the 
Tumor Registry) and, thus, does not represent a dif-
ference in patient population at the time of diagnosis 
but, rather, may represent one potential impact of the 
navigator program.  
 
 
Table 1. Patient characteristics 
  Standard 
Management 
(n = 103) 
Navigation 
Available 
(n = 219) 
Combined 
Population 
(n = 322) 
Median Age  54 years  56 years  55.5 years 
Race  %  %  % 
White  41.7  53.4  49.7 
Black  55.3  44.3  47.8 
Other  2.9  2.4  2.4 
Clinical Presentation       
Breast mass  27.7  45.2  39.9 
Abnormal mammogram  67.0  45.2  51.8 
Unknown  5.3  9.7  8.3 
Insurance       
Commercial insurance  7.8  11.0  9.9 
Medicare  35.9  28.8  31.1 
Medicaid  17.5  49.8  39.4 
Uninsured  37.9*  9.6  18.6 
Other  1.0  0.9  0.9 
Histology       
Invasive ductal  79.6  72.6  74.8 
Invasive lobular  2.9  3.7  3.4 
Carcinoma-in-situ  9.7  7.3  8.1 
Others  6.9  16.7  12.7 
Stage       
0  10.7  14.6  13.4 
I  24.3  23.7  23.9 
IIA  29.1  23.3  25.2 
IIB  14.6  15.5  15.2 
IIIA  8.7  7.8  8.1 
IIIB  5.8  4.1  4.7 
IIIC  0  0.9  0.6 
IV  5.8  10.0  8.7 
Estrogen Receptor       
Positive  46.6  57.6  54.1 
Negative  23.3  23.5  23.4 
Unknown/CIS  30.1  18.9  22.5 
Progesterone Receptor       
Positive  41.7  50.7  47.8 
Negative  27.2  29.5  28.8 
Unknown/CIS  31.1  19.8  23.5 
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 The navigators were expected to help and guide 
subjects with Medicaid and/or Medicare applications 
and with local arrangements for financial assistance *. 
There was no substantive difference in tumor charac-
teristics in the two groups of women. The majority of 
tumors were infiltrating ductal carcinomas. The final 
pathologic  stage  is  very  similar  between  the  two 
groups. Overall, 13% of women had carcinoma-in-situ. 
Of the 279 women with invasive cancer, 49% had local 
disease,  41%  regional  disease,  and  10%  distant  dis-
ease. 
The time from initial presentation, either the date 
of  an  abnormal  screening  test  or  the  date  of  initial 
evaluation of a breast mass, to the date of definitive 
therapy was shorter during the period of time when 
patient navigation was available. The median time to 
first treatment was 9 days shorter (42 days compared 
to 33 days) after the institution of the navigator pro-
gram. There was a much more dramatic difference in 
the mean values (70 days, 95% CI (47-94) in the pre 
navigator group compared to 48 days, 95% CI (41-55) 
in  the  post  navigator  group,  p  =  0.006).  The  mean 
values, however, were strongly influenced by a very 
small number of women who chose to delay therapy 
for  months  (and  in  two  cases,  years)  after  initial 
presentation. Overall, 67% of women in the pre navi-
gator  group  received  definitive  therapy  within  60 
days of initial presentation; 75% of women in the post 
navigator  group  had  received  definitive  therapy 
within 60 days of presentation (Figure 1). For the large 
majority of women in both groups, the initial defini-
tive  therapy  was  surgery:  in  the  standard  therapy 
group  6%  of  women  received  systemic  therapy 
(chemotherapy or hormonal therapy) as their initial 
treatment,  in  the  navigation  group  16%  of  women 
received  systemic  therapy  as  their  initial  treatment. 
For most women, the choice to use systemic therapy 
as initial treatment was made in the setting of distant 
metastatic  disease.  In  the  later  time  period,  a  small 
number of women with earlier stage cancer also re-
ceived systemic therapy as their first treatment. 
 The  only  other  pre-treatment  variable  signifi-
cantly associated with time between clinical presenta-
tion and treatment was patient age (p = 0.02), with 
younger  women  experiencing  a  greater  delay  in 
therapy. Race, insurance type, and mode of clinical 
presentation were not associated with time to treat-
ment. Multivariable regression analysis confirmed the 
independent association of both navigator availability 
(p = 0.04) and patient age (p = 0.02) in time to initial 
treatment. 
 The median time from surgery to the beginning 
of adjuvant therapy was the same in both groups, 40 
days. The mean times were, likewise, very similar: pre 
navigator group, 48 days (95% CI 39-56), post navi-
gator group, 43 days (95% CI 38-48), p = 0.62.  
 Overall survival was not influenced by the pa-
tient navigation program (Figure 2), as would be ex-
pected, given the relatively minor impact of the pro-
gram upon evaluation and management time.  
 
 
Figure 1. Time to Definitive Therapy for Breast Cancer  Journal of Cancer 2011, 2 
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Figure 2. Survival. 
 
Discussion 
 Implementation of a patient navigation program 
at this safety net hospital had a very modest effect on 
the  time  from  symptom  presentation  to  first  treat-
ment, decreasing the median time by 9 days, from 42 
to 33 days. This study focused on processes of care 
from the time of identification of a suspicious finding 
through treatment of the cancer. We were unable to 
obtain accurate data on the first step in formal health 
care access—time to access of primary care, although 
the  wait  time  for  new  patient  appointments  at  our 
local  community  health  centers  and  hospital  based 
clinics  is  typically  less  than  one  month,  suggesting 
that navigation to improve access earlier in the pro-
cess of care would have also had very limited impact 
upon the early course of care. 
Not surprisingly, given the relative ease of access 
to specialty care, patient navigation was not shown to 
have any influence on stage of disease at presentation 
or survival of breast cancer patients. The women in 
this  study  had  more  advanced  breast  cancer  at 
presentation than that observed in the U.S. population 
as described by the SEER data over a similar time pe-
riod.[13]  Local  disease  was  observed  in  49%  (com-
pared with 61% nationally), regional disease in 41% 
(31% nationally) and distant disease in 10% (6% na-
tionally).  This  more  advanced  disease,  primarily 
manifested by a shift from local to regional disease, 
may be the result of limited access to or use of pri-
mary  care,  lower  routine  breast  cancer  screening 
among our patient population, or biologically more 
aggressive disease. It does not; however, appear to be 
a marker of inability to successfully use the variety of 
services available for the diagnosis and treatment of 
cancer. 
 One significant difference in the population that 
received navigation services was the shift from com-
plete lack of health insurance to enrollment in Medi-
caid.  This  variable  was  measured  six  months  after 
diagnosis,  not  at  the  time  of  presentation.  It  is  cer-
tainly possible that interaction with the patient navi-
gator was influential in patients successfully applying 
and  receiving  Medicaid.  This  is  a  complex  process 
requiring careful adherence to data requests and close 
follow-up. However, this analysis covered a time pe-
riod during which the hospital implemented a variety 
of  programs  designed  to  increase  Medicaid  enroll-
ment and these concurrent events likely confound the 
interpretation of the insurance data. 
 The  definition  of  patient  navigation  varies  be-
tween institutions. [11] It is generally recognized to be 
a barrier focused intervention provided to individual 
patients to assist with accessing cancer related care. 
[14] Culturally sensitive education and psychosocial 
support are frequently combined with case manage-
ment  functions,  including  careful  testing  follow-up, 
appointment scheduling, and care coordination. [15]  Journal of Cancer 2011, 2 
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The navigation function typically is limited to a set of 
services required to complete a component of cancer 
care  and,  therefore,  distinguishes  itself  from  tradi-
tional case management and social services functions. 
Further, the focus of navigation programs has been on 
those members of the community felt to be the most 
vulnerable to adverse disparities in cancer care and 
outcomes.  While  patient  navigation  programs  re-
ported in the medical literature employ a variety of 
techniques to provide improved access and elimina-
tion of barriers, the majority tend to focus on one area 
of cancer care: screening for malignancy and the ac-
tivities  surrounding  this  event.  [14,  16-20]  Both  ad-
herence  to  recommended  screening  guidelines  (for 
breast, colorectal, cervical, and prostate cancer) and 
timely follow-up and resolution of screening abnor-
malities have been examined. Our study is one of the 
few to investigate the effect of patient navigation on 
the course of care and clinical outcome of women with 
a  cancer  diagnosis.  Only  the  report  of  the  original 
program from the Cancer Control Center of Harlem 
included  a  similarly  large  number  of  women  with 
cancer. [10] In that study, a dramatic shift in breast 
cancer stage at diagnosis was observed after the im-
plementation of a comprehensive cancer management 
and  outreach  program  that  included  navigator  ser-
vices. The investigators saw the proportion of women 
with Stage III/IV breast cancer at diagnosis decrease 
from  49%  prior  to  program  implementation  to  21% 
after program implementation. In our study, a similar 
shift to earlier stage disease could not be documented 
(Stage  III/IV  disease  in  the  usual  management 
group—20.3%, in the navigation group—22.8%). This 
could be explained as navigation began at the time of 
diagnosis, which is too late in the process to influence 
outcomes, such as stage of diagnosis. 
 The  primary  weakness  of  this  study  is  the 
non-randomized,  historical  control,  study  design, 
leaving results open to differential outside influences. 
We  expect  that  this  explains  the  difference  in  the 
proportion of subjects covered by the state Medicaid 
program,  as  described  earlier.  There  were  no  other 
obvious changes in the local or regional health care 
structure that would have been expected to influence 
our observations. A potential strength of this research 
design was the opportunity to observe the impact of 
the  Patient  Navigator  Program  on  all  women  with 
breast  cancer  at  the  institution,  rather  than  solely 
those agreeing to participate in the program. While a 
more favorable effect of the navigator program may 
have  been  observed  if  the  analysis  were  limited  to 
those who took advantage of the navigator services, 
this likely would represent women expected to have 
better outcomes as a result of their demonstrated ac-
tive involvement in pursuit of medical care. By stud-
ying the impact of a navigator program in all women 
with breast cancer at a single institution, we poten-
tially provide a more accurate description of the ef-
fectiveness of similar programs on the larger popula-
tion.  
Understanding that participation in the naviga-
tion  program  was  voluntary  and  there  could  have 
been a selection bias from a subject prospective in the 
population  studied  in  the  post  navigation  era.  Our 
aim was to look at the overall impact of patient navi-
gation  in  this  community  based  program,  where  it 
was established to help subjects have an easy access to 
barriers to care. 
Data collection was limited to cancers diagnosed 
and treated at the host institution. To the best of au-
thor’s capacity all eligible persons with cancer were 
captured and included in the study. If patients sought 
treatment at other hospitals, they were excluded from 
the study as mentioned earlier. As this was a retro-
spective  analysis,  other  sociodemographic  factors 
which  can  also  influence  treatment  related  barriers 
such as spouse and family support, living alone, ed-
ucation, income level, employment at the time after 
diagnosis were not available at the time of the study. 
Improvement in overall survival with navigation 
intervention at the time of clinical presentation could 
not  be  expected  as  several  factors  including  stage, 
biology of the disease, treatment received all play a 
major role in affecting survival. Our intention in this 
study was to evaluate the timeliness of care provided, 
as one possible factor influencing survival. However 
as overall survival is determined by many patient and 
disease  characteristics,  including  stage,  prognostic 
factors,  and  treatment  provided,  patient  navigation 
would  most  likely  not  influence  overall  survival  in 
this patient population without substantially affecting 
timeliness of care. 
 Patient navigation in the context of the activity 
studied  in  this  analysis  also  included  collaboration 
with the local hospital-based clinics and community 
health centers to facilitate patient access to specialty 
diagnostic and treatment services, direct patient con-
tact to assist with education and information, coordi-
nation of consultations and diagnostic testing, assis-
tance  with  transportation  and  communication,  and 
psychosocial support over the course of cancer care. 
Review of the data from this study, when considered 
in  the  context  of  the  available  medical  literature, 
suggests that maximum benefit from navigation pro-
grams will only be observed if characteristics of the 
local health care setting are carefully considered.  
Programs that focus on easing access to cancer 
diagnostic and treatment services may be quite useful  Journal of Cancer 2011, 2 
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and  effective  in  some  settings,  whereas  other  com-
munities may benefit far more from community out-
reach  programs  that  emphasize  routine  use  of  pri-
mary  care  and  cancer  screening  services.  It  is  very 
unlikely that a single programmatic approach to the 
observed  disparities  in  cancer  outcomes  will  be 
equally effective in all settings across this country. 
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